NZ574200A - Methods and medicaments for administration of ibuprofen and famotidine - Google Patents

Methods and medicaments for administration of ibuprofen and famotidine

Info

Publication number
NZ574200A
NZ574200A NZ574200A NZ57420007A NZ574200A NZ 574200 A NZ574200 A NZ 574200A NZ 574200 A NZ574200 A NZ 574200A NZ 57420007 A NZ57420007 A NZ 57420007A NZ 574200 A NZ574200 A NZ 574200A
Authority
NZ
New Zealand
Prior art keywords
famotidine
ibuprofen
administration
unit dose
tid
Prior art date
Application number
NZ574200A
Other languages
English (en)
Inventor
George Tidmarsh
Barry L Golombik
Puneet Sharma
Original Assignee
Horizon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/489,269 external-priority patent/US20080021078A1/en
Priority claimed from US11/489,272 external-priority patent/US20080020040A1/en
Application filed by Horizon Therapeutics Inc filed Critical Horizon Therapeutics Inc
Publication of NZ574200A publication Critical patent/NZ574200A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ574200A 2006-07-18 2007-07-17 Methods and medicaments for administration of ibuprofen and famotidine NZ574200A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/489,269 US20080021078A1 (en) 2006-07-18 2006-07-18 Methods and medicaments for administration of ibuprofen
US11/489,272 US20080020040A1 (en) 2006-07-18 2006-07-18 Unit dose form for administration of ibuprofen
US89737107P 2007-01-24 2007-01-24
PCT/US2007/073716 WO2008011426A2 (en) 2006-07-18 2007-07-17 Methods and medicaments for administration of ibuprofen

Publications (1)

Publication Number Publication Date
NZ574200A true NZ574200A (en) 2011-02-25

Family

ID=38957561

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ574200A NZ574200A (en) 2006-07-18 2007-07-17 Methods and medicaments for administration of ibuprofen and famotidine

Country Status (13)

Country Link
EP (2) EP2043637B8 (https=)
JP (1) JP2009543885A (https=)
AT (1) ATE539747T1 (https=)
AU (1) AU2007275360B2 (https=)
BR (1) BRPI0714937A2 (https=)
CA (1) CA2657928C (https=)
DK (1) DK2043637T3 (https=)
ES (1) ES2380747T3 (https=)
IL (1) IL196425A (https=)
NZ (1) NZ574200A (https=)
PL (1) PL2043637T3 (https=)
PT (1) PT2043637E (https=)
WO (1) WO2008011426A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
WO2008091957A2 (en) * 2007-01-24 2008-07-31 Horizon Therapeutics, Inc. Pharmaceutical compositions containing famotidine and ibuprofen and having improved content uniformity
WO2013054352A1 (en) 2011-08-17 2013-04-18 Cadila Healthcare Limited Pharmaceutical compositions of ibuprofen and famotidine
CA2889711A1 (en) 2012-10-29 2014-05-08 Arizona Board Of Regents On Behalf Of University Of Arizona Predictive markers for polyamine inhibitor cancer therapies
WO2015163832A1 (en) 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
WO2015195120A1 (en) 2014-06-18 2015-12-23 Arizona Board Of Regents On Behalf Of University Of Arizona Carcinoma diagnosis and treatment based on odc1 genotype
WO2016130918A1 (en) 2015-02-12 2016-08-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating neuroblastoma
WO2017075576A1 (en) * 2015-10-30 2017-05-04 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
KR20260033630A (ko) 2015-10-30 2026-03-10 캔서 프리벤션 파마수티컬스, 인코포레이티드 에플로르니틴 및 설린닥, 고정된 용량 조합 제제
JP2022532766A (ja) 2019-05-17 2022-07-19 キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド 家族性腺腫性ポリポーシスを処置するための方法
EP4181912A1 (en) * 2020-07-15 2023-05-24 Schabar Research Associates LLC Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
US12514846B2 (en) 2020-07-15 2026-01-06 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach
CA3124579C (en) 2020-07-15 2026-03-31 Schabar Research Associates Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
WO2023068839A1 (ko) * 2021-10-21 2023-04-27 한화제약주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 안정성이 개선된 필름코팅 정제

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056143B2 (ja) 1979-08-02 1985-12-09 山之内製薬株式会社 アミジン誘導体ならびにその製造法
US4543370A (en) 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4802924A (en) 1986-06-19 1989-02-07 Colorcon, Inc. Coatings based on polydextrose for aqueous film coating of pharmaceutical food and confectionary products
HU196775B (en) 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
CA2144155A1 (en) * 1992-09-29 1994-04-14 Robert T. Sims Ibuprofen-h2 antagonist combinations
US5976578A (en) * 1996-10-10 1999-11-02 Mcneil-Ppc, Inc. Liquid antacid compositions
US6251945B1 (en) 1999-01-14 2001-06-26 Knoll Aktiengesellschaft Pharmaceutical mixture comprising a combination of a profen and other active compounds
DE10003757A1 (de) 2000-01-28 2001-08-02 Knoll Ag Ibuprofen-Wirkstoffzubereitung
EP2260837A1 (en) * 2001-06-01 2010-12-15 Pozen, Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DE10153934A1 (de) 2001-11-06 2003-05-22 Basf Ag Verfahren zur Kristallisation von Profenen
CA2554012A1 (en) * 2003-01-21 2004-08-05 Smartrix Technologies Inc. Oral dosage formulation
JP2006076956A (ja) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk 胃炎の治療・予防用配合剤
WO2007012019A2 (en) * 2005-07-18 2007-01-25 Horizon Therapeutics, Inc. Medicaments containing famotidine and ibuprofen and administration of same
DE102005049001A1 (de) 2005-10-11 2007-04-12 Basf Ag Verfahren zur Herstellung von direkttablettierbaren Ibuprofen-Formulierungen

Also Published As

Publication number Publication date
IL196425A (en) 2014-07-31
PT2043637E (pt) 2012-04-12
BRPI0714937A2 (pt) 2013-03-26
EP2043637B8 (en) 2012-03-28
AU2007275360A1 (en) 2008-01-24
EP2043637A4 (en) 2009-11-25
DK2043637T3 (da) 2012-05-07
EP2438919A1 (en) 2012-04-11
CA2657928C (en) 2014-12-02
PL2043637T3 (pl) 2012-06-29
CA2657928A1 (en) 2008-01-24
WO2008011426A2 (en) 2008-01-24
WO2008011426A3 (en) 2008-12-04
EP2043637B1 (en) 2012-01-04
IL196425A0 (en) 2009-11-18
JP2009543885A (ja) 2009-12-10
EP2043637A2 (en) 2009-04-08
ES2380747T3 (es) 2012-05-18
ATE539747T1 (de) 2012-01-15
AU2007275360B2 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
NZ574200A (en) Methods and medicaments for administration of ibuprofen and famotidine
US8067451B2 (en) Methods and medicaments for administration of ibuprofen
US8501228B2 (en) Stable compositions of famotidine and ibuprofen
CA2615496C (en) Medicaments containing famotidine and ibuprofen and administration of same
CN101516368B (zh) 用于施用布洛芬的方法和药物
US20080021078A1 (en) Methods and medicaments for administration of ibuprofen
HK1169038A (en) Compositions comprising famotidine and ibuprofen as well as compositions comprising 25 mg to 28 mg famotidine
US20130078287A1 (en) Pharmaceutical compositions of ibuprofen and an h2 receptor antagonist
AU2006269894B2 (en) Medicaments containing famotidine and ibuprofen and administration of same
US20130236538A1 (en) Pharmaceutical compositions of ibuprofen and famotidine

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 JUL 2017 BY CPA GLOBAL

Effective date: 20140605

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 JUL 2018 BY COMPUTER PACKAGES INC

Effective date: 20170701

ASS Change of ownership

Owner name: HORIZON MEDICINES LLC, US

Effective date: 20181009

LAPS Patent lapsed